Please assess the completion status of the following clinical trial:

Trial Title: Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Malignant, histologically proved, non resectable pleural Mesothelioma~* In case of pleural effusion, a talc pleurodesis, although not recommended, is allowed in accordance with current local practice, at the time of diagnostic thorascopy, with inclusion CT scan performed after pleurodesis.~* ECOG Performance status 0-2~* Mesothelioma with only pleural effusion without uni- or bidimensionally measurable disease will be eligible (adapted RECIST criteria)~* At least 18 years of age, less than 76 years of age~* Radiation therapy of thoracocentis tract (3 x 7Gy) performed before beginning medical study treatment, and the interval between thoracoscopic procedure and radiation will not exceed 28 days~Exclusion Criteria:~* Prior chemotherapy~* Brain metastasis~* History of cerebral vascular accident (CVA) or transient ischemic attack

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard Chemotherapy
- 2 (Type: EXPERIMENTAL): Standard Chemotherapy + bevacizumab (Avastin)

Based on this trial design, predict the completion outcome and termination type (if applicable).